OvaScience to Present at the JMP Securities Life Sciences Conference
WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that Company management will present
at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016
at 11:30 am ET at the St. Regis New York.
A live audio webcast of the presentation can be accessed by visiting the
investor section of the Company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
two weeks following the presentation.
About OvaScience
OvaScience, Inc. (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because it believes women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S.
Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment, OvaPrime treatment and OvaTure treatment. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to: the possibility that international IVF clinics that we work
with may determine not to provide or continue providing the AUGMENT
treatment or OvaPrime treatment, or to delay providing such treatments,
based on clinical efficacy, safety or commercial, logistic, regulatory
or other reasons; the science underlying our treatments (including the
AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our
ability to obtain regulatory approval or licenses where necessary for
our treatments; our ability to develop our treatments on the timelines
we expect, if at all; our ability to commercialize our treatments, on
the timelines we expect, if at all; as well as those risks more fully
discussed in the “Risk Factors” section of our most recently filed
Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The
forward-looking statements contained in this press release reflect our
current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.
###
Contacts
Media and Investor Contact:
OvaScience
Rebecca
J. Peterson, 617-420-8736
rpeterson@ovascience.com
